Liver cancer Archives -

Keytruda fluffs its lines in prostate, liver cancer trials

Phil Taylor immuno-oncology, Keytruda, Liver cancer, Merck & Co, Oncology, Prostate cancer 0 Comment

Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver

Keytruda fluffs its lines in prostate, liver cancer trials

https://pharmaphorum.com/news/keytruda-fluffs-its-lines-in-prostate-liver-cancer-trials/

Digital/ News/ News/ News/ Oncology

Median Tech debuts AI-focused unit for cancer trial support

Phil Taylor digital, digital health, iBiopsy, imaging, Liver cancer, lung cancer, Median Technologies, Oncology 0 Comment

Medical imaging specialist Median Technologies has launched a new business unit that will provide decision-making tools – underpinned

Median Tech debuts AI-focused unit for cancer trial support

https://pharmaphorum.com/news/median-tech-debuts-ai-focused-unit-for-cancer-trial-support/

Market Access/ News/ News/ News/ Oncology

AZ closes on FDA verdict on tremelimumab in liver cancer

Phil Taylor AstraZeneca, immuno-oncology, Liver cancer, Oncology, tremelimumab 0 Comment

AstraZeneca’s anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after

AZ closes on FDA verdict on tremelimumab in liver cancer

https://pharmaphorum.com/news/az-closes-on-fda-verdict-on-tremelimumab-in-liver-cancer/

News/ News/ Oncology

Keytruda’s liver cancer approval secured by new study

Phil Taylor immuno-oncology, Keytruda, Liver cancer, Merck & Co, Oncology 0 Comment

Merck & Co’s FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial

Keytruda’s liver cancer approval secured by new study

https://pharmaphorum.com/news/keytrudas-liver-cancer-approval-secured-by-new-study/

News/ News/ Oncology

BMS pulls speedy Opdivo approval for liver cancer in US

Phil Taylor Bristol-Myers Squibb, fda, immuno-oncology, Keytruda, Liver cancer, Merck & Co, Oncology, Opdivo 0 Comment

Bristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for

BMS pulls speedy Opdivo approval for liver cancer in US

https://pharmaphorum.com/news/bms-pulls-speedy-opdivo-approval-in-liver-cancer-in-us/

News/ News/ Oncology

Exelixis’ Cabometyx misses survival target in liver cancer trial

Phil Taylor Cabometyx, Exelixis, Ipsen, Liver cancer 0 Comment

Exelixis has suffered a blow to its efforts to expand the use of Cabometyx into additional indications after

Exelixis’ Cabometyx misses survival target in liver cancer trial

https://pharmaphorum.com/news/exelixis-cabometyx-misses-survival-target-in-liver-cancer-trial/

News/ News/ Oncology

NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drug

Phil Taylor aTTP, Avastin, Cablivi, Liver cancer, NICE, Roche, Sanofi, Tecentriq 0 Comment

Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option

NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drug

https://pharmaphorum.com/news/nice-okays-roche-liver-cancer-immunotherapy-sanofis-rare-disease-drug/

News/ News/ Oncology/ Top stories

Merck & Co/Eisai eye kidney cancer use for immunotherapy combination

Richard Staines cancer, Eisai, Liver cancer, Merck & Co 0 Comment

Merck & Co and Eisai are to file results from a phase 3 trial testing a combination of

Merck & Co/Eisai eye kidney cancer use for immunotherapy combination

https://pharmaphorum.com/news/merck-co/

News/ News/ Oncology

Europe approves Roche’s Tecentriq liver cancer combination

Richard Staines Bayer, cancer, Liver cancer, Roche 0 Comment

The European Commission has approved Roche’s Tecentriq immunotherapy, in combination with its established cancer drug Avastin, for patients

Europe approves Roche’s Tecentriq liver cancer combination

https://pharmaphorum.com/news/europe-approves-roches-tecentriq-liver-cancer-combination/

Trending

Liver cancer

Login